Sunday, January 17, 2021

Tag: COVID-19 therapeutics

Mesoblast Crashed on Poor DSMB Report Leaving CytoDyn as Sole Survivor...

Only Mesoblast (NASDAQ:MESO) and CytoDyn Inc. (OTCMKS: CYDY) had mortality as a primary endpoint in severe to critical COVID-19.